Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Alnylam files patent infringement lawsuits against Pfizer, Moderna

Published 03/17/2022, 07:56 AM
Updated 03/17/2022, 11:41 AM
© Reuters. FILE PHOTO: Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

© Reuters. FILE PHOTO: Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) - Alnylam Pharmaceuticals Inc on Thursday filed lawsuits in Delaware federal court against Pfizer Inc (NYSE:PFE) and Moderna (NASDAQ:MRNA) Inc, claiming their multibillion-dollar mRNA COVID-19 vaccines infringe one its patents.

Alnylam said it was seeking damages over the use of lipid nanoparticle (LNP) technology used in the Pfizer/BioNTech and Moderna vaccines to carry and deliver genetic material into the body.

Representatives for Pfizer and Moderna did not immediately respond to requests for comment on the lawsuits.

Shares of Moderna, whose lone commercial product is its COVID vaccine, were off about 4%. Pfizer shares were up 1.7% and Alnylam was up 2%.

Alnylam's lawsuit against Moderna says it discussed licensing its technology to the company in late 2013 or 2014, and shared confidential information about it with Moderna at the time.

The lawsuit against Pfizer said Alnylam's LNP technology is also "essential" to the effectiveness and safety of Pfizer's vaccine.

Arbutus Biopharma (NASDAQ:ABUS) Corp separately sued Moderna in Delaware federal court last month, claiming Moderna's COVID-19 vaccine infringes its patents, which also relate to RNA-delivery technology.

The U.S. National Institutes of Health has also implied it may sue Moderna over a vaccine-related patent application that NIH says should have listed its scientists as co-inventors.

© Reuters. FILE PHOTO: Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

Alnylam asked the court for an undisclosed amount of money damages from Pfizer and Moderna. It said in a statement it does not intend to take action that impedes the production, sale or distribution of the vaccines.

Moderna has said its vaccine earned the company $17.7 billion in revenue in 2021. Pfizer said last month that it expected $32 billion in revenue from its vaccine this year.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.